BACKGROUND: The clinical implications of emergent HIV drug resistance on samples with low-level viraemia (LLV <1000 copies/ml) remain unclear. We undertook the present analysis to evaluate the impact of emergent HIV drug resistance at LLV on the risk of subsequent virologic failure. METHODS: One thousand, nine hundred and sixty-five patients had genotype results at LLV. Risk of virologic failure (≥1000 copies/ml) after LLV was evaluated by Kaplan-Meier analysis and Cox proportional hazards regression. Resistance was assessed using the Stanford algorithm or virtual phenotypes. Patients were grouped into four susceptibility categories ('GSS' or 'vPSS') during LLV, corresponding to the number of 'active' drugs prescribed: <1; 1-1.5; 2-2.5; and ≥3. RESULTS: A total of 1702 patients with follow-up on constant therapy were eligible for analysis. Participants excluded due to changing therapy or loss to follow-up before their next observation had mostly similar characteristics to included participants. There was a 'dose-dependent' increase in the hazard ratio for virologic failure with susceptibility categories at LLV. Compared with a GSS of at least 3, hazard ratios for virologic failure were 1.4 for GSS 2-2.5; 2.0 for GSS 1-1.5; and 3.0 for GSS less than 1 (P < 0.001). Numerous sensitivity analyses confirmed these findings. CONCLUSION: Our results demonstrate that emergent HIV drug resistance at LLV is strongly associated with subsequent virologic failure. Furthermore, we uncovered a 'dose-dependent' increase in the hazard ratio for virologic failure with decreasing GSS estimated at the time of LLV. On the basis of these findings, we propose that resistance genotyping be encouraged for HIV-infected individuals on antiretroviral therapy experiencing low-level viraemia.
BACKGROUND: The clinical implications of emergent HIV drug resistance on samples with low-level viraemia (LLV <1000 copies/ml) remain unclear. We undertook the present analysis to evaluate the impact of emergent HIV drug resistance at LLV on the risk of subsequent virologic failure. METHODS: One thousand, nine hundred and sixty-five patients had genotype results at LLV. Risk of virologic failure (≥1000 copies/ml) after LLV was evaluated by Kaplan-Meier analysis and Cox proportional hazards regression. Resistance was assessed using the Stanford algorithm or virtual phenotypes. Patients were grouped into four susceptibility categories ('GSS' or 'vPSS') during LLV, corresponding to the number of 'active' drugs prescribed: <1; 1-1.5; 2-2.5; and ≥3. RESULTS: A total of 1702 patients with follow-up on constant therapy were eligible for analysis. Participants excluded due to changing therapy or loss to follow-up before their next observation had mostly similar characteristics to included participants. There was a 'dose-dependent' increase in the hazard ratio for virologic failure with susceptibility categories at LLV. Compared with a GSS of at least 3, hazard ratios for virologic failure were 1.4 for GSS 2-2.5; 2.0 for GSS 1-1.5; and 3.0 for GSS less than 1 (P < 0.001). Numerous sensitivity analyses confirmed these findings. CONCLUSION: Our results demonstrate that emergent HIV drug resistance at LLV is strongly associated with subsequent virologic failure. Furthermore, we uncovered a 'dose-dependent' increase in the hazard ratio for virologic failure with decreasing GSS estimated at the time of LLV. On the basis of these findings, we propose that resistance genotyping be encouraged for HIV-infected individuals on antiretroviral therapy experiencing low-level viraemia.
Authors: Bart Winters; Elke Van Craenenbroeck; Koen Van der Borght; Pierre Lecocq; Jorge Villacian; Lee Bacheler Journal: J Virol Methods Date: 2009-08-03 Impact factor: 2.014
Authors: Viviane D Lima; Vikram S Gill; Benita Yip; Robert S Hogg; Julio S G Montaner; P Richard Harrigan Journal: J Infect Dis Date: 2008-07-01 Impact factor: 5.226
Authors: P Clevenbergh; J Durant; P Halfon; P del Giudice; V Mondain; N Montagne; J M Schapiro; C A Boucher; P Dellamonica Journal: Antivir Ther Date: 2000-03
Authors: Ian Williams; Duncan Churchill; Jane Anderson; Marta Boffito; Mark Bower; Gus Cairns; Kate Cwynarski; Simon Edwards; Sarah Fidler; Martin Fisher; Andrew Freedman; Anna Maria Geretti; Yvonne Gilleece; Rob Horne; Margaret Johnson; Saye Khoo; Clifford Leen; Neal Marshall; Mark Nelson; Chloe Orkin; Nicholas Paton; Andrew Phillips; Frank Post; Anton Pozniak; Caroline Sabin; Roy Trevelion; Andrew Ustianowski; John Walsh; Laura Waters; Edmund Wilkins; Alan Winston; Mike Youle Journal: HIV Med Date: 2012-09 Impact factor: 3.180
Authors: Joseph J Eron; David A Cooper; Roy T Steigbigel; Bonaventura Clotet; Patrick Yeni; Kim M Strohmaier; Anthony J Rodgers; Richard J Barnard; Bach-Yen T Nguyen; Hedy Teppler Journal: Antivir Ther Date: 2014-10-27
Authors: Matthew L Romo; Jessie K Edwards; Aggrey S Semeere; Beverly S Musick; Mark Urassa; Francesca Odhiambo; Lameck Diero; Charles Kasozi; Gad Murenzi; Patricia Lelo; Katarzyna Wyka; Elizabeth A Kelvin; Annette H Sohn; Kara K Wools-Kaloustian; Denis Nash Journal: Clin Infect Dis Date: 2022-09-10 Impact factor: 20.999
Authors: V Carnimeo; I A Pulido Tarquino; S Fuentes; D Vaz; L Molfino; N Tamayo Antabak; R M Cuco; A Couto; S Lobo; J de Amaral Fidelis; J S Mulassua; I Ciglenecki; T Ellman; B Schramm Journal: JAC Antimicrob Resist Date: 2021-05-12
Authors: Kristina L Bajema; Robin M Nance; Joseph A C Delaney; Ellen Eaton; Thibaut Davy-Mendez; Maile Y Karris; Richard D Moore; Joseph J Eron; Benigno Rodriguez; Kenneth H Mayer; Elvin Geng; Cindy Garris; Michael S Saag; Heidi M Crane; Mari M Kitahata Journal: AIDS Date: 2020-11-15 Impact factor: 4.632